Delta-tocotrienol.

Alpha-tocopherol reduces tocotrienol uptake and attenuates tocotrienol activity, which is why tocotrienol products are made low in alpha-tocopherol.

Tocopherols and delta-tocotrienol share the intestinal lipid route and the hepatic transfer protein, so a large tocopherol dose lowers the tocotrienol fraction delivered.

A tocotrienol complex already supplies delta alongside gamma and alpha forms, so combining the two simply adds to the total tocotrienol load on the same carriers.

Tocotrienols lower HMG-CoA reductase activity, and the same mevalonate pathway makes coenzyme Q10, so supplying CoQ10 replaces what the pathway produces less of.

Both act on HMG-CoA reductase, the rate-setting step of the body's own cholesterol synthesis, so their effects fall on the same step rather than on separate ones.

Ascorbate reduces the oxidised chromanol head of tocotrienol back to its active form, the same recycling couple that operates for tocopherols.

Tocotrienol interrupts lipid radical chains while selenium-dependent glutathione peroxidases remove the resulting hydroperoxides.

Tocotrienols are fat soluble and depend on bile and a lipid vehicle for micelle formation, so a fat carrier raises the fraction absorbed.

Glutathione keeps ascorbate reduced, and ascorbate is what recycles the tocotrienol chromanol, so the glutathione pool supports tocotrienol turnover.

Tocotrienols partition into the same lipid phase as long-chain polyunsaturated oils and slow their peroxidation, which is why they appear together in oil blends.

Alpha-tocopherol and the tocotrienols share hepatic alpha-tocopherol transfer protein and the same intestinal lipid absorption route, and the transfer protein binds alpha-tocopherol far more tightly. Large concurrent doses of alpha-tocopherol therefore lower circulating tocotrienol concentrations. Formulators who want measurable delta-tocotrienol levels usually separate the two in time or keep added alpha-tocopherol low. This is a pharmacokinetic interaction, not an effect on any clinical outcome.

Mixed tocopherol preparations are dominated by alpha and gamma forms, which compete with delta-tocotrienol for the same absorption and transfer machinery. Gamma-tocopherol is itself displaced by alpha-tocopherol, so the whole family behaves as one competing pool. A product that pairs them delivers less of each than either alone would suggest. The interaction is about blood levels, not about which form is preferable.

Delta-tocotrienol and resveratrol have been given together in a randomised trial that measured circulating microRNA and metabolic markers. Both compounds act on redox-sensitive transcriptional signalling, which is the stated rationale for combining them. The reported endpoints are markers rather than clinical outcomes. Evidence for the pair rests on that single combination trial.

Tocotrienols are oil-soluble and depend on bile-salt mixed micelles to cross the intestinal wall. Phospholipid emulsifiers such as lecithin disperse the oil into finer droplets and enlarge the surface available for lipolysis. This is standard practice for fat-soluble actives rather than a claim about any health endpoint. The effect is on delivery, not on potency per milligram absorbed.

Phosphatidylcholine is the principal emulsifying phospholipid in bile and in most lecithin preparations, and it stabilises tocotrienol in an emulsified phase. Supplements often carry it as the vehicle rather than as a second active. It shortens the time an oil droplet needs to be broken down before micelle formation. The relationship is one of delivery chemistry.

Carotenoids and tocotrienols are both carried in the same intestinal mixed micelles and can crowd one another at high single doses. The competition is well described for the fat-soluble class in general. The practical consequence is lower measured absorption of one or both, which is a pharmacokinetic marker rather than an outcome. Splitting large doses across meals is the usual formulation answer.

Lycopene is highly lipophilic and partitions into the same micellar phase that carries tocotrienol. Co-dosing at high levels can reduce the fraction of either that reaches the blood. The size of the effect depends on the dose and the fat content of the meal. Nothing here concerns a clinical endpoint.

Lutein shares the micellar and lipoprotein transport route used by tocotrienols, so the two can compete when both are given in a single fatty dose. The interaction is documented for the fat-soluble nutrient class rather than for this specific pair. It affects measured plasma levels only.

Menaquinone-7 and delta-tocotrienol both carry unsaturated isoprenoid side chains and travel in the same chylomicron and lipoprotein fractions. They are commonly co-formulated in a single oil base for that reason. Whether one changes the other's plasma level in humans has not been established. The rationale is chemical similarity, not a measured combination effect.

Astaxanthin sits across the membrane bilayer while tocotrienol's short unsaturated tail keeps it mobile within the same lipid phase, so the two intercept lipid radicals in overlapping compartments. Both are dosed in oil and are chemically compatible in a softgel. The additive framing comes from membrane redox chemistry rather than from a trial of the pair.

Dihydrolipoic acid can reduce oxidised vitamin E radicals back to their active form, directly and by way of ascorbate and glutathione. That recycling relationship is described for the vitamin E family, which includes the tocotrienols. It is a mechanism established in biochemistry rather than a measured clinical benefit of the pair.

Quercetin donates electrons at the lipid-water interface and can spare chain-breaking antioxidants operating inside the membrane. Delta-tocotrienol works in that membrane phase. The pairing is chemically coherent and has not been tested together in people, so it stays at the level of mechanism.

Berberine acts mainly by stabilising LDL receptor messenger RNA, while tocotrienols act post-translationally on HMG-CoA reductase. Two different control points on the same pathway is the usual reason products combine them. Both effects are on lipid-handling markers. No trial of the two together grounds this row.

Piperine slows several intestinal and hepatic metabolising enzymes and is added to many lipid-soluble botanical preparations for that reason. Whether it changes tocotrienol exposure specifically has not been measured. The row records a common formulation pairing, not a demonstrated effect.

Krill oil is a phospholipid-rich carrier that emulsifies readily and can hold tocotrienol in a dispersed phase. The pairing is a delivery choice made at the bench. It carries its own long-chain fatty acids, which is a separate matter from the tocotrienol content.